Acetylation inactivates the transcriptional repressor BCL6

Nature Genetics

Volumn 32, Issue 4, 2002, Pages 606-613

  Bereshchenko, Oksana R ^a   Gu, Wei ^a   Dalla Favera, Riccardo ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE;

ACETYLATION; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BINDING AFFINITY; CELL CYCLE; CELL TRANSFORMATION; CONTROLLED STUDY; GENE CONTROL; GENE FUNCTION; GENETIC TRANSCRIPTION; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; PHYSIOLOGY; PRIORITY JOURNAL; PROTO ONCOGENE; TRANSCRIPTION REGULATION;

ACETYLATION; ACETYLTRANSFERASES; AMINO ACID SUBSTITUTION; ANIMALS; B-LYMPHOCYTES; CELL CYCLE PROTEINS; CELL LINE; CELLS, CULTURED; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GENES, REPORTER; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LUCIFERASES; POINT MUTATION; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; RATS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0036898253     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1018     Document Type: Article

References (50)

1. Ye, B.H. et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 262, 747-750 (1993).
2. Ye, B.H. et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B-cell lymphoma. EMBO J. 14, 6209-6217 (1995).
3. Baron, B.W. et al. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas. Proc. Natl. Acad. Sci. USA 90, 5262-5266 (1993).
4. Kerckaert, J.P. et al. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nature Genet. 5, 66-70 (1993).
5. Zollman, S., Godt, D., Prive, G.G., Couderc, J.L. & Laski, F.A. The BTB domain, found primarily in zinc finger proteins, defines an evolutionarily conserved family that includes several developmentally regulated genes in Drosophila. Proc. Natl. Acad. Sci. USA 91, 10717-10721 (1994).
6. Chang, C.C., Ye, B.H., Chaganti, R.S. & Dalla-Favera, R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor Proc. Natl. Acad. Sci. USA 93, 6947-6952 (1996).
7. Seyfert, V.L., Allman, D., He, Y. & Staudt, L.M. Transcriptional repression by the proto-oncogene BCL-6. Oncogene 12, 2331-2342 (1996).
8. Dhordain, P. et al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res. 26, 4645-4651 (1998).
9. Dhordain, P. et al. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc. Natl. Acad. Sci. USA 94, 10762-10767 (1997).
10. Wong, C.W. & Privalsky, M.L. Components of the SMRT corepressor complex exhibit distinctive interactions with the POZ domain oncoproteins PLZF, PLZF-RARα, and BCL-6. J. Biol. Chem. 273, 27695-27702 (1998).
11. Cattoretti, G. et al. BCL-6 protein is expressed in germinal-center B cells. Blood 86, 45-53 (1995).
12. Onizuka, T. et al. BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal-center B cells and their neoplastic counterparts. Blood 86, 28-37 (1995).
13. Rajewsky, K. Clonal selection and learning in the antibody system. Nature 381, 751-758 (1996).
14. Ye, B, H. et al. The BCL-6 proto-oncogene controls germinal-center formation and Th2-type inflammation. Nature Genet. 16, 161-170 (1997).
15. Dent, A.L., Shaffer, A.L., Yu, X., Allman, D. & Staudt, L.M. Control of inflammation, cytokine expression and germinal-center formation by BCL-6. Science 276, 589-592 (1997).
16. Shaffer, A.L. et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell-cycle control. Immunity 13, 199-212 (2000).
17. Reljic, R., Wagner, S.D., Peakman, L.J. & Fearon, D.T. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J. Exp. Med. 192, 1841-1848 (2000).
18. Harris, M.B. et al. Transcriptional repression of Stat6-dependent interleukin-4-induced genes by BCL-6: Specific regulation of iepsilon transcription and immunoglobulin E switching. Mol. Cell Biol. 19, 7264-7275 (1999).
19. Niu, H., Ye, B.H. & Dalla-Favera, R. Antigen receptor signaling induces MAP kinase-mediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 12, 1953-1961 (1998).
20. Allman, D. et al. BCL-6 expression during B-cell activation. Blood 87, 52S7-5268 (1996).
21. Shen, H.M., Peters, A., Baron, B., Zhu, X. & Storb, U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 280, 1750-1752 (1998).
22. Migliazza, A. et al, Frequent somatic hypermutation of the 5′ noncoding region of the BCL6 gene in B-cell lymphoma. Proc. Natl. Acad. Sci. USA 92, 12520-12524 (1995).
23. Pasqualucci, L. et al. BCL-6 mutations in normal germinal center B cells: Evidence of somatic hypermutation acting outside Ig loci. Proc. Natl. Acad Sci. USA 95, 11816-11821 (1998).
24. Artiga, M.J. et al. A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas. Am. J. Pathol. 160, 1371-1380 (2002).
25. Sterner, D.E. & Berger, S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64, 435-459 (2000).
26. Barlev, N.A. et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8, 1243-1254 (2001).
27. Gu, W. & Roeder, R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
28. Roth, S.Y., Denu, J.M. & Allis, C.D. Histone acetyltransferases. Annu. Rev. Biochem. 70, 81-120 (2001).
29. Chan, H.M., Krstic-Demonacos, M., Smith, L., Demonacos, C. & La Thangue, N.B. Acetylation control of the retinoblastoma tumour-suppressor protein. Nature Cell Biol. 3, 667-674 (2001).
30. Martinez-Balbas, M.A., Bauer, U.M., Nielsen, S.J., Brehm, A. & Kouzarides, T, Regulation of E2F1 activity by acetylation. EMBO J. 19, 662-671 (2000).
31. Ogryzko, V.V., Schlitz, R.L., Russanova, V., Howard, B.H. & Nakatani, Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87, 953-959 (1996).
32. Boyes, J., Byfield, P., Nakatani, Y. & Ogryzko, V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396, 594-598 (1998).
33. Chan, H.M. & La Thangue, N.B. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. 114, 2363-2373 (2001).
34. Zhang, W., Bone, J.R., Edmondson, D, G., Turner, B.M. & Roth, S.Y. Essential and redundant functions of histone acetylation revealed by mutation of target lysines and loss of the Gcn5p acetyltransferase. EMBO J. 17, 3155-3167 (1998).
35. Ng, H.H. & Bird, A. Histone deacetylases: Silencers for hire. Trends Biochem. Sci. 25, 121-126 (2000).
36. Albagli, O. et al. Multiple domains participate in distance-independent LAZ3/BCL6-mediated transcriptional repression. Biochem. Biophys. Res. Commun. 220, 911-915 (1996).
37. Huynh, K.D. & Bardwell, V.J. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT. Oncogene 17, 2473-2484 (1998).
38. Marks, P.A., Richon, VM. & Rifkind, R.A. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92, 1210-1216 (2000).
39. Vaziri, H. et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159 (2001).
40. Luo, J. et al. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107, 137-148 (2001).
41. Iida, S. et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nature Genet. 17, 226-230 (1997).
42. Sakaguchi, K. et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 12, 2831-2841 (1998).
43. Zhang, H., Okada, S., Hatano, M., Okabe, S. & Tokuhisa, T. A new functional domain of Bcl6 family that recruits histone deacetylases. Biochim. Biophys. Acta 1540, 188-200 (2001).
44. Cress, W.D. & Seto, E. Histone deacetylases, transcriptional control, and cancer. J. Cell Physiol. 184, 1-16 (2000).
45. Imai, S., Armstrong, C.M., Kaeberlein, M. & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795-800 (2000).
46. Guarente, L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 14, 1021-1026 (2000).
47. Luo, J., Su, F., Chen, D., Shiloh, A. & Gu, W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408, 377-381 (2000).
48. Polyak, K., Xia, Y., Zweier, J.L., Kinzler, K.W. & Vogelstein, B. A model for p53-induced apoptosis. Nature 389, 300-305 (1997).
49. Gaidano, G. et al. p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 88, S413-5417 (1991).
50. Moller, M.B., Gerdes, A.M., Skjodt, K., Mortensen, L.S. & Pedersen, N.T. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Clin. Cancer Res. 5, 1085-1091 (1999).